MegaPro Biomedical Co

MegaPro Biomedical Co Gross Margin

The Gross Margin of MegaPro Biomedical Co (6827.TWO) as of Nov 18, 2026 is -122,807.14 %. In the previous year, Gross Margin was -92,227.78 % — a change of 33.16% (lower).

Gross Margin

-122,807.14 %

YoY

33.16%

Last updated:

Gross Margin of MegaPro Biomedical Co is 2024 -122,807.14 % . Gross Margin of MegaPro Biomedical Co was 2023 -92,227.78 % . It decreases by 33.16% lower compared to the previous year.

For MegaPro Biomedical Co, the gross margin of -122,807.1% is down versus 100.0% a few years ago.

The MegaPro Biomedical Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2020
100.00 TWD
Jan 1, 2023
-92,227.78 TWD
Jan 1, 2024
-122,807.14 TWD
The MegaPro Biomedical Co Gross Margin history
YEARGross MarginYoY
-122,807.14 %+33.16%
-92,227.78 %-92,327.78%
100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MegaPro Biomedical Co Stock analysis

What does MegaPro Biomedical Co do? MegaPro Biomedical Co., Ltd. generates revenue through its development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's primary products are MPB-1514, MPB-1523, MPB-1734, and MPB-2043, each targeting specific medical conditions. MPB-1514 treats anemia in chronic kidney disease patients via intravenous injection, while MPB-1523 diagnoses hepatocellular carcinoma through intravenous administration. MPB-1734 addresses solid tumors with intravenous treatment, and MPB-2043 aids in diagnosing metastases in peripheral lymph nodes of cancer sites. These products are sold to healthcare providers and medical institutions requiring advanced diagnostic and therapeutic solutions. The company focuses on two core technology platforms: nanoparticle and nanocell, which underpin its product development. Its product portfolio targets chronic kidney disease, hepatocellular carcinoma, solid tumors, and cancer metastasis diagnostics. These applications are directed toward medical professionals and facilities specializing in oncology and nephrology. The firm's revenue model relies on the commercialization of these specialized drug ingredients for targeted medical treatments and diagnostics. MegaPro Biomedical's products are designed for intravenous use across various medical conditions, positioning the company within the biotechnology sector. Its revenue streams come from the sale of these proprietary drug ingredients to hospitals, clinics, and research institutions. The company's market segments include healthcare providers treating kidney disease, cancer diagnostics, and oncology-focused medical facilities seeking innovative therapeutic solutions. MegaPro Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MegaPro Biomedical Co stock

Gross Margin of MegaPro Biomedical Co is -122,807.14 % in 2024.

Gross Margin of MegaPro Biomedical Co changed from -92,227.78 % to -122,807.14 %, representing a 33.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin MegaPro Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's MegaPro Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — MegaPro Biomedical Co

All Key Metrics — MegaPro Biomedical Co